Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31349660 | 0.86 | JAK1 (0.37) | JAK1SMN1; SMN2MAPK1KDM4EALDH1A1 | |
| SCHEMBL31349539 | 0.85 | CCNT1 (0.37) | JAK1JAK2JAK3 | |
| SCHEMBL25314937 | 0.84 | AR (0.36) | — | |
| SCHEMBL30506875 | 0.84 | AR (0.36) | — | |
| SCHEMBL25924334 | 0.84 | AR (0.36) | — | |
| SCHEMBL25924928 | 0.78 | PRPS1 (0.38) | PRPS1 | |
| SCHEMBL25317119 | 0.78 | PRPS1 (0.38) | PRPS1 | |
| SCHEMBL30507104 | 0.78 | PRPS1 (0.38) | PRPS1 | |
| SCHEMBL31349640 | 0.77 | SNCA (0.31) | — | |
| SCHEMBL25315066 | 0.75 | CDK9 (0.32) | JAK1SMN1; SMN2MAPK1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025015106-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |